Cardiff Oncology, Inc. — Form 8-K
Filed July 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 32/100
What the filing says
Cardiff Oncology issued 9,303,136 shares of common stock at $1.05/share plus accompanying warrants to purchase 9,303,136 additional shares at $1.31/share, totaling $10,050,000 in gross proceeds. Closing occurred July 14, 2026 under registered Form S-3 offering (File 333-285327). Placement agent H.C. Wainwright Co., LLC facilitated the transaction. Warrants exercisable beginning January 2027 (or Authorized Share Increase Date, whichever is later) through July 2031.
Why this rating
Modest capital raise (~5% of market cap) using standard registered direct offering structure. No material business operational changes disclosed. Routine financing activity relative to company size.
See more from July 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.